Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Winkler

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Cancer|March 21, 2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemiaGeorg Hopfinger, Raymonde Busch, Natali Pflug, et al.
Journal of Biomolecular Screening|August 17, 2005
NanoStore: a concept for logistical improvements of compound handling in high-throughput screeningNeil Benson, Helen F Boyd, Jeremy R Everett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupStephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.
Blood|April 12, 2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialPeter Dreger, Hartmut Döhner, Fabienne McClanahan, et al.
Bioorganic & Medicinal Chemistry|May 8, 2013
Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanismDouglas Marcotte, Weike Zeng, Jean-Christophe Hus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Blood|October 11, 2012
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterationsJennifer Edelmann, Karlheinz Holzmann, Florian Miller, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Parkinsonism & Related Disorders|February 18, 2019
Development of evidence-based quality indicators for deep brain stimulation in patients with Parkinson's disease and first year experience of implementation of a nation-wide registryKirsten Haas, Stephanie Stangl, Frank Steigerwald, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Cancer|March 21, 2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemiaGeorg Hopfinger, Raymonde Busch, Natali Pflug, et al.
Journal of Biomolecular Screening|August 17, 2005
NanoStore: a concept for logistical improvements of compound handling in high-throughput screeningNeil Benson, Helen F Boyd, Jeremy R Everett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupStephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.
Blood|April 12, 2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialPeter Dreger, Hartmut Döhner, Fabienne McClanahan, et al.
Bioorganic & Medicinal Chemistry|May 8, 2013
Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanismDouglas Marcotte, Weike Zeng, Jean-Christophe Hus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Blood|October 11, 2012
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterationsJennifer Edelmann, Karlheinz Holzmann, Florian Miller, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Parkinsonism & Related Disorders|February 18, 2019
Development of evidence-based quality indicators for deep brain stimulation in patients with Parkinson's disease and first year experience of implementation of a nation-wide registryKirsten Haas, Stephanie Stangl, Frank Steigerwald, et al.
Pageof 10